Interleukin Genetics announced the appointment of Mark Carbeau as its new CEO and director.
Before joining Interleukin, Carbeau was co-founder and CEO of Diagnostyx, a technology-based healthcare company.
Carbeau replaces Kenneth Kornman, DDS, PhD, who has served as president and CEO since August 2012. Kornman will continue to serve as president, chief scientific officer, and a director.
James M. Weaver, chairman of the Interleukin Genetics board, said in a press release that he was excited to bring Carbeau to the company.
"Mark is a leader with an outstanding track record of building high-growth healthcare businesses, including taking multiple products from ideation to commercialization and category leadership," Weaver said.